Glycemic variability assessed by continuous glucose monitoring in hospitalized patients with community-acquired pneumonia

• Published in: BMC pulmonary medicine 2022-03, Vol.22 (1), p.83-83, Article 83
• Main Authors: Olsen, Mikkel Thor, Dungu, Arnold Matovu, Klarskov, Carina Kirstine, Jensen, Andreas Kryger, Lindegaard, Birgitte, Kristensen, Peter Lommer
• Format: Article
• Language: English
• Subjects: Bacterial pneumonia; Chronic obstructive pulmonary disease; Community-acquired infections; Community-acquired pneumonia; Complications and side effects; Continuous glucose monitoring; Corticosteroids; Diabetes mellitus; Drug therapy; Glucocorticoid-induced hyperglycemia; Glycemic variability; Hospital patients; Hyperglycemia; Pneumonia; Risk factors; Statistics; Type 2 diabetes
• ISSN: 1471-2466; 1471-2466
• DOI: 10.1186/s12890-022-01874-7

Glycemic variability (GV) has only been sparsely studied in patients with community-acquired pneumonia (CAP). This study aimed to quantify in-hospital GV in CAP patients, including determining the impact of type 2 diabetes mellitus (T2DM) and glucocorticoid (GC) treatment on GV. This is a prospective cohort study of CAP patients (N = 40) with or without T2DM and treated or not with GCs. The primary endpoint was GV measured as glucose standard deviation (SD), coefficient of variation (CV), and postprandial glucose excursions (PPGE) based on continuous glucose monitoring (CGM). Analysis of glucose data was split into daytime and nighttime when possible. Patients included had a mean age of 74 (range 55 to 91) years. SD (95%CI) increased by a factor of 1.93 (1.40 to 2.66) and 2.29 (1.38 to 3.81) in patients with T2DM and not treated with GCs during the daytime and the nighttime, respectively (both P